AxoGen (NASDAQ:AXGN – Get Free Report) and RxSight (NASDAQ:RXST – Get Free Report) are both small-cap healthcare companies, but which is the better stock? We will contrast the two businesses based on the strength of their analyst recommendations, valuation, risk, profitability, institutional ownership, earnings and dividends.
Profitability
This table compares AxoGen and RxSight’s net margins, return on equity and return on assets.
| Net Margins | Return on Equity | Return on Assets | |
| AxoGen | -13.36% | -8.90% | -6.47% |
| RxSight | -36.80% | -17.35% | -14.70% |
Analyst Recommendations
This is a summary of recent recommendations for AxoGen and RxSight, as reported by MarketBeat.
| Sell Ratings | Hold Ratings | Buy Ratings | Strong Buy Ratings | Rating Score | |
| AxoGen | 1 | 2 | 11 | 1 | 2.80 |
| RxSight | 3 | 7 | 2 | 0 | 1.92 |
AxoGen currently has a consensus price target of $51.73, indicating a potential upside of 41.80%. RxSight has a consensus price target of $8.17, indicating a potential upside of 66.78%. Given RxSight’s higher probable upside, analysts clearly believe RxSight is more favorable than AxoGen.
Insider and Institutional Ownership
80.3% of AxoGen shares are owned by institutional investors. Comparatively, 78.8% of RxSight shares are owned by institutional investors. 2.4% of AxoGen shares are owned by company insiders. Comparatively, 10.1% of RxSight shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock will outperform the market over the long term.
Valuation & Earnings
This table compares AxoGen and RxSight”s top-line revenue, earnings per share (EPS) and valuation.
| Gross Revenue | Price/Sales Ratio | Net Income | Earnings Per Share | Price/Earnings Ratio | |
| AxoGen | $225.21 million | 8.71 | -$15.70 million | ($0.68) | -53.65 |
| RxSight | $127.58 million | 1.60 | -$38.94 million | ($1.13) | -4.34 |
AxoGen has higher revenue and earnings than RxSight. AxoGen is trading at a lower price-to-earnings ratio than RxSight, indicating that it is currently the more affordable of the two stocks.
Risk & Volatility
AxoGen has a beta of 1.17, meaning that its stock price is 17% more volatile than the S&P 500. Comparatively, RxSight has a beta of 1.15, meaning that its stock price is 15% more volatile than the S&P 500.
Summary
AxoGen beats RxSight on 12 of the 15 factors compared between the two stocks.
About AxoGen
AxoGen, Inc., together with its subsidiaries, develops and commercializes technologies for peripheral nerve regeneration and repair worldwide. The company’s products include Avance Nerve Graft, a biologically active off-the-shelf processed human nerve allograft for bridging severed peripheral nerves without the comorbidities associated with a second surgical site; AxoGuard Nerve Connector, a porcine submucosa extracellular matrix (ECM) coaptation aid for tensionless repair of severed peripheral nerves; AxoGuard Nerve Protector, a porcine submucosa ECM product that is used to wrap and protect damaged peripheral nerves, as well as reinforces the nerve reconstruction while preventing soft tissue attachments; and Axoguard HA+ Nerve Protector, a processed porcine submucosa ECM base layer with a hyaluronate-alginate gel coating designed to provide short- and long-term protection for peripheral nerve injuries. Its products also comprise Axoguard Nerve Cap, a porcine submucosa ECM product that is used to protect a peripheral nerve end, as well as separates the nerve from the surrounding environment to reduce the development of symptomatic or painful neuroma; and AxoTouch two-point discriminator, a tool that is used for measuring the innervation density of surface area of the skin. The company provides its products to hospitals, surgery centers, and military hospitals, plastic reconstructive surgeons, orthopedic and plastic hand surgeons, and various oral and maxillofacial surgeons. AxoGen, Inc. is headquartered in Alachua, Florida.
About RxSight
RxSight, Inc., a commercial-stage medical device company, engages in the research and development, manufacture, and sale of light adjustable intraocular lenses (LAL) used in cataract surgery in the United States and internationally. It offers RxSight system that enables doctors to customize and enhance the visual acuity for patients after cataract surgery. The company's RxSight system includes RxSight Light Adjustable Lens, a special photosensitive material that changes shape and power. RxSight light delivery device, an office-based light treatment device that delivers UV light in a programmed pattern to modify the LAL based on the visual correction needed to achieve desired vision after cataract surgery. It primarily serves cataract doctors. The company was formerly known as Calhoun Vision, Inc. and changed its name to RxSight, Inc. in February 2017. RxSight, Inc. was incorporated in 1997 and is headquartered in Aliso Viejo, California.
Receive News & Ratings for AxoGen Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for AxoGen and related companies with MarketBeat.com's FREE daily email newsletter.
